

22nd



EACCME EVENT LEE21-01648

Les Pensières Center for Global Health

Veyrier-du-Lac – France

May 9-20, 2022

FINAL COURSE PROGRAM

Organized by

The Mériem Foundation
and the University of Geneva

With the co-sponsorship of

-
- Bill & Melinda Gates Foundation
 - Centers for Disease Control and Prevention (CDC)
 - Coalition for Epidemic Preparedness Innovations (CEPI)
 - European Centre for Disease Prevention and Control (ECDC)
 - European & Developing Countries Clinical Trials Partnership (EDCTP)
 - European Society for Paediatric Infectious Diseases (ESPID)
 - Johns Hopkins Bloomberg School of Public Health
 - National Foundation for Infectious Diseases (NFID)
 - National Institutes of Health (NIAID, NIH) and Fogarty International Center
 - World Health Organization



**UNIVERSITÉ
DE GENÈVE**



| MONDAY 09 MAY 2022 | | |
|--|--|---|
| 09:00 | Opening and objectives of the Course | Philippe Duclos , Director, ADVAC |
| 09:30 | Briefing | Bénédicte Pansier , Director, Les Pensières Center for Global Health |
| SESSION 1a - THE MULTIFACETED NATURE OF VACCINOLOGY | | Chairperson: Adam Finn , University of Bristol, UK |
| 09:40-10:05 | Opening Lecture: How to develop a new program of immunization | David Salisbury , Centre on Global Health Security, UK |
| 10:05-10:25 | Discussion | |
| 10:25-10:55 | Break | |
| 10:55-11:20 | Access to vaccination in GAVI countries and at global level | Aurelia Nguyen , GAVI, the Vaccine Alliance, Geneva |
| 11:20-11:40 | Discussion | |
| 11:40-11:50 | Time for students to reflect personally on the learnings of the morning | |
| 11:50-13:20 | Lunch | |
| 13:20-13:45 | A global perspective on the regulation of vaccines | Norman Baylor , Biologics Consulting Inc., USA |
| 13:45-14:05 | Discussion | |
| 14:05-14:30 | COVID Vaccines | Melanie Saville , CEPI, UK |
| 14:30-14:50 | Discussion | |
| 14:50-15:20 | Break | |
| 15:20-16:50 | Session 1b: Special lectures from Industry | |
| 16:50-17:00 | Time for students to reflect personally on the learnings of the afternoon | |
| 17:00-19:00 | Self-presentation of individual participants (background, interests in life...) & Welcome reception | |

| TUESDAY 10 MAY 2022 | | |
|--------------------------------------|---|--|
| SESSION 2 - HOW VACCINES WORK | | Chairperson: Daniel Pinschewer, University of Basel, Switzerland |
| 09:00-09:25 | How are vaccine responses elicited? What a vaccinologist should know about the basic aspects of immunological responses (a) B-cell responses | Claire-Anne Siegrist, University of Geneva |
| 09:25-09:45 | Discussion | |
| 09:45-10:15 | Break | |
| 10:15-10:40 | What a vaccinologist should know about the basic aspects of immunological responses (b) T-cell responses | Claire-Anne Siegrist, University of Geneva |
| 10:40-11:00 | Discussion | |
| 11:00-11:25 | Use and limitations of correlates of immunity in vaccinology | Andrew Pollard, University of Oxford, UK |
| 11:25-11:45 | Discussion | |
| 11:45-11:55 | Time for students to reflect personally on the learnings of the morning | |
| 11:55-13:25 | Lunch | |
| 13:25-13:50 | Vaccines and mucosal immunity | Adam Finn, University of Bristol, UK |
| 13:50-14:10 | Discussion | |
| 14:10-14:55 | Vaccines and immunological memory Quiz and general discussion | Claire-Anne Siegrist, University of Geneva |
| 14:55-15:25 | Break | |
| 15:25-15:50 | Immunological memory | Rafi Ahmed, Emory University, USA |
| 15:50-16:10 | Discussion | |
| 16:10-16:35 | Advances in vaccine and immunization technologies | Cristina Casetti, NIH-NIAID, USA |
| 15:35-16:55 | Discussion | |
| 16:55-17:05 | Time for students to reflect personally on the learnings of the afternoon | |
| 17:05-18:30 | Debate on mandatory vs voluntary vaccination | Chaired by Hanna Nohynek, National Institute for Health and Welfare, Helsinki Adam Finn, University of Bristol, UK & Noni MacDonald, Dalhousie University, Canada |

| WEDNESDAY 11 MAY 2022 | | |
|--|--|--|
| SESSION 3 - DECISION-MAKING IN VACCINE RESEARCH AND PRECLINICAL DEVELOPMENT | | Chairperson: Emily Erbelding, Director, DMID, NIH, USA |
| 09:00-09:25 | How do vaccines cause adverse events? | Narendra Arora, INCLIN, India |
| 09:25-09:45 | Discussion | |
| 09:45-10:10 | Vaccine adjuvants | Martin Friede, WHO, Geneva |
| 10:10-10:30 | Discussion | |
| 10:30-11:10 | Break | |
| 11:10-11:35 | From pre-clinical research to vaccine development: Examples of go-no-go decisions | Veronica Gambillara, GlycoEra AG, Switzerland |
| 11:35-11:55 | Discussion | |
| 11:55-12:05 | Time for students to reflect personally on the learnings of the morning | |
| 12:05-13:35 | Lunch | |
| 13:35-14:00 | The complexity of quality control in vaccine manufacturing | Philippe Juvin, Sanofi Pasteur, Lyon, France |
| 14:00-14:20 | Discussion | |
| 14:20-14:50 | Break | |
| 14:50-16:40 | Regulatory considerations A round-table debate | Chair: Emily Erbelding, Director, DMID/NIAID, NIH, USA Norman Baylor, Biologics Consulting Group, Inc., USA, Pieter Neels, Vaccine-advice, Belgium, Saeedeh Fakhrzadeh, Food and Drug Administration, Iran, Ozzie Berger, GSK and David Greenberg, Sanofi Pasteur |
| 16:40-16:50 | Time for students to reflect personally on the learnings of the afternoon | |
| 16:50-18:30 | Debate: From ideas to implementation: The realities of funding for vaccine research and development | Emily Erbelding, DMID, NIH, USA (Chairperson), Veronica Gambillara, GlycoEra AG, Switzerland, Penny Heaton, J&J, and selected ADVAC students |

| THURSDAY 12 MAY 2022 | | |
|--|--|---|
| SESSION 4 - ASSESSING VACCINES IN CLINICAL TRIALS (I) | | Chairperson: Hanna Nohynek, National Institute for Health and Welfare, Helsinki, Finland |
| 09:00-09:25 | Clinical trials: an overview of issues to be considered | Myron Levine, University of Maryland, USA |
| 09:25-09:45 | Discussion | |
| 09:45-10:10 | Introduction to statistical aspects of clinical trials 1- Defining sample size | Peter Smith, London School of Hygiene and Tropical Medicine, UK |
| 10:10-10:30 | Discussion | |
| 10:30-10:40 | Time for students to reflect personally on the learnings of the first part of the morning | |
| 10:40-11:10 | Break | |
| 11:10-13:50 | How to design, recruit volunteers for, and analyze the results of selected phase II trials Small group exercise 1: Seven Groups - Themes: Group 1 <i>S. aureus</i> Group 2 Ebola Group 3 Dengue Group 4 GBS Group 5 RSV Group 6 Men B Group 7 Coronavirus | Facilitators: Veronica Gambillara Pieter Neels Norman Baylor Edwin Asturias Kari Johansen Adam Finn Emily Erbeling |
| 12:40-13:10 <i>Buffet lunch</i> | | |
| 13.50-14.15 | Assessing herd protection and vaccine effectiveness (and use for licensure) | John Clemens, International Centre for Diarrheal Disease Research, Bangladesh (icddr,b) |
| 14:15-14:35 | Discussion | |
| 14:35-15:00 | Clinical trials: role of a Data Safety Monitoring Board (DSMB) (with several examples of intervention) | Robert Heyderman, University College London, UK |
| 15:00-15:20 | Discussion | |
| 15:20-15:50 | Break | |
| 15:50-16:30 | THE 6th LAMBERT LECTURE Understanding mRNA vaccines | Drew Weissman, University of Pennsylvania, Philadelphia, USA |
| 16:30-16:50 | Discussion | |
| 16:50-17:00 | Time for students to reflect personally on the learnings of the morning | |
| 17:00-18:20 | Debate: Dealing with human challenge studies. | Chairperson: Penny Heaton, J&J Introduction on Challenge trials by Penny Heaton J&J, 20 mins. Debate between Joris Vandeputte, IABS and Pieter Neels, Vaccine-advice, Belgium |

| FRIDAY 13 MAY 2022 | | |
|---|--|--|
| SESSION 5 - VACCINE SAFETY - ASSESSMENT OF ADVERSE EFFECTS | | Chairperson: Kari Johansen, Public Health Agency, Sweden |
| 09:00-09:25 | Lessons from previous adverse effects of vaccination and assessment of causal relationships | Madhav Balakrishnan, WHO, Geneva |
| 09:25-09:45 | Discussion | |
| 09:45-10:10 | Vaccination and immune-mediated diseases | Paul-Henri Lambert, University of Geneva |
| 10:10-10:30 | Discussion | |
| 10:30-10:50 | Break | |
| 10:50-11:15 | Population-based post-licensure surveillance | Nick Andrews, Public Health England, UK |
| 11:15-11:35 | Discussion | |
| 11:35-11:45 | Time for students to reflect personally on the learnings of the morning | |
| 11:45-13:15 | Lunch | |
| 13:15-13:40 | Thrombotic Thrombocytopenia Syndrome (TTS) following vaccination with COVID-19 non-replicant adenovirus vector-based vaccines | Kawsar Talaat, Johns Hopkins Bloomberg, School of Public Health, Baltimore, USA |
| 13:40-14:00 | Discussion | |
| 14:00-14:25 | Immunization safety in low and middle income country vaccination programs | Philippe Duclos, ADVAC |
| 14:25-14:45 | Discussion | |
| 14:45-15:10 | Addressing vaccine hesitancy and acceptance | Noni McDonald, Dalhousie University, Halifax, Canada |
| 15:10-15:30 | Discussion | |
| 15:30-15:50 | Break | |
| SESSION 6 – ASSESSING VACCINES IN CLINICAL TRIALS (II) | | Chairperson: Hanna Nohynek, National Institute for Health and Welfare, Helsinki, Finland |
| 15:50-16:15 | Introduction to statistical aspects of clinical trials 2- Statistical assessment and reporting of phase 3 trials | Peter Smith, LSHTM, UK |
| 16:15-16:35 | Discussion | |
| 16:35-18:35 | Small group exercise 2: Designing and analyzing the results of selected phase 3 trials | |
| | Introduction to the Group Work Exercise | Hanna Nohynek, National Institute for Health and Welfare, Helsinki, Finland |
| | Seven Groups | Facilitators: Nick Andrews, Brad Gessner, Penny Heaton, Kari Johansen, Pieter Neels, Hanna Nohynek, Peter Smith |
| 18:35-18:45 | Time for students to reflect personally on the learnings of the afternoon | |

SATURDAY 14 MAY 2022

| | | |
|-----------------------------------|---|--|
| SESSION 7 - ETHICAL ISSUES | | Chairperson: Kari Johansen , Public Health Agency, Sweden |
| 09:00-09:25 | Principles, guidelines and frameworks for ethical considerations in clinical trials of vaccines | Catherine Slack , University of KwaZulu-Natal, South Africa |
| 09:25-09:45 | Discussion | |
| 09:45-10:10 | Applied ethics in immunization programs and practice | Noni McDonald , Dalhousie University, Halifax, Canada |
| 10:10-10:30 | Discussion | |
| 10:30-10:40 | Pick up and bring coffee/tea/fruit to group exercise | |
| 10:40-13:00 | Small group exercise 3: Ethical considerations in COVID-19 vaccine trials | Coordinated by Kari Johansen, Betty Dodet (Dodet Bioscience, France) and Catherine Slack |
| | Seven Groups | Facilitators: Edwin Asturias, Betty Dodet, Noni McDonald, Kari Johansen, Pieter Neels, Adam Finn, Romina Libster |
| 13:00-13:10 | Time for students to reflect personally on the learnings of the morning | |
| 13:10-14:10 | Lunch | |
| 14:10-15:40 | OPTIONAL SESSIONS 1. AEFI: Causality assessment 2. Monitoring and evaluation of vaccine programs (WUENIC,EPI review...). Use of various tools in immunization programs e.g. ODK tools. 3.The issue of poor data quality and challenges related with secondary data sources, and how we ensure reporting of quality data. | Madhav Balakrishnan , WHO, Geneva Carolina Danovaro , WHO, Geneva Marta Gacic-Dobo , WHO Geneva |

| MONDAY 16 MAY 2022 | | |
|---|---|--|
| 08:50-0900 | Ethical considerations in COVID-19 vaccine trials: Recap | Catherine Slack , University of KwaZulu-Natal, South Africa |
| SESSION 8 - INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES | | Chairperson: Anna Durbin , Johns Hopkins B. School of Public Health, Baltimore, USA |
| 09:00-09:25 | Disease burden and the public health value of vaccines | Annelies Wilder-Smith , Consultant, WHO |
| 09:25-09:45 | Discussion | |
| 09:45-10:10 | Health economics (including modelling) as a tool in analyzing vaccine policy options | Mark Miller , NIH, USA |
| 10:10-10:30 | Discussion | |
| 10:30-11:00 | Break | |
| 11:00-11:25 | Challenges and solutions in making evidence-based national vaccination policies and recommendations | Philippe Duclos , ADVAC |
| 11:25-11:45 | Discussion | |
| 11:45-11:55 | Time for students to reflect personally on the learnings of the morning | |
| 11:55-13:25 | Lunch | |
| 13:25-13:50 | Dengue vaccines | Anna Durbin , Johns Hopkins Bloomberg School of Public Health, Baltimore, USA |
| 13:50-14:10 | Discussion | |
| 14:10-14:35 | Response to polysaccharide and conjugate vaccines | David Goldblatt , University College London, UK |
| 14:35-14:55 | Discussion | |
| 14:55-15:25 | Break | |
| 15:25-16:05 | Pneumococcal conjugate vaccines: Efficacy and limitations of available vaccines and existing and potential vaccination strategies | Ron Dagan , Soroka Medical Center, Beer Sheva, Israel Keith Klugman , Bill & Melinda Gates Foundation, USA |
| 16:05-16:35 | Discussion | |
| 16:35-17:00 | Non-specific effects of vaccines | Nigel Curtis , The Royal Children's Hospital, Melbourne |
| 17:00-17:20 | Discussion | |
| 17:20-18:20 | Small group exercise 4: Decision-making for the evaluation and impact assessment of new vaccines introduced in selected countries: safety and effectiveness Objective: To learn what facts are needed in a decision-making process and how other factors influence the outcome Part 1: Preparation and data analysis Seven groups - Themes: Group 1 Rotavirus Group 2 HPV Group 3 Coronavirus LMIC Group 4 Coronavirus HIC Group 5 Malaria Group 6 Shingles Group 7 Tdap | Organized by Kari Johansen, Hanna Nohynek and Edwin Asturias Facilitators: Umesh Parashar Mark Miller Brad Gessner & Hanna Nohynek Kari Johansen Kathy Neuzil Keipp Talbot Janet Englund |
| 18:20-18:30 | Time for students to reflect personally on the learnings of the afternoon | |
| 18:30-19:30 | Debate: Does a vaccine have to protect against a VPD that kills to matter to politicians and parents? | Chair: Ron Dagan , Soroka Medical Center, Beer Sheva, Israel Presenters: Keipp Talbot , Vanderbilt University, USA; Kari Johansen , Public Health Institute, Sweden; and Mark Miller NIH, USA and selected participants |

| TUESDAY 17 MAY 2022 | | |
|---|---|--|
| SESSION 8 (Ctd) - INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES | | Chairperson: Anna Durbin , Johns Hopkins B. School of Public Health, Baltimore, USA |
| 08:30-08:55 | HPV vaccines | Margaret Stanley , Cambridge University, UK |
| 08:55-09:15 | Discussion | |
| 09:15-09:35 | Vaccine responses and efficacy in the elderly (including the specific example of the Zoster vaccine) | Keipp Talbot , Vanderbilt University, USA |
| 09:35-09:55 | Discussion | |
| 09:55-10:25 | Break | |
| 10:25-10:50 | Meningococcal vaccines | Ray Borrow , Public Health England, UK |
| 10:50-11:10 | Discussion | |
| 11:10-11:35 | Population biology of bacterial pathogens and its importance for vaccination strategies | Richard Moxon , Oxford University, UK |
| 11:35-11:55 | Discussion | |
| 11:55-12:05 | Time for students to reflect personally on the learnings of the morning | |
| 12:05-13:35 | Lunch | |
| 13:35-14:00 | Success and challenges with rotavirus and norovirus vaccines | Umesh Parashar , Centers for Disease Control, Atlanta, USA |
| 14:00-14:20 | Discussion | |
| 14:20-14:45 | Cancer vaccines | Lana Kandalajt , Centre Hospitalier Universitaire Vaudois, Suisse |
| 14:45-15:05 | Discussion | |
| 15:05-15:35 | Break | |
| 15:35-16:35 | <p>Small group exercise 4: Decision-making for the evaluation and impact assessment of new vaccines introduced in selected countries: safety and effectiveness</p> <p>Part 2: Presentations, discussion and conclusion</p> <p>Seven groups- Themes:</p> <ul style="list-style-type: none"> Group 1 Rotavirus Group 2 HPV Group 3 Coronavirus LMIC Group 4 Coronavirus HIC Group 5 Malaria Group 6 Shingles Group 7 Tdap | <p>Facilitators:</p> <p>Umesh Parashar Mark Miller Brad Gessner & Hanna Nohynek Kari Johansen Kathy Neuzil Keipp Talbot Janet Englund</p> |
| 16:35-17:00 | Impact of vaccination on disease epidemiology | Roy Anderson , Director, London Centre for Neglected Tropical Disease Research, Imperial College, London |
| 17:00-17:20 | Discussion | |
| 17:20-17:30 | Time for students to reflect personally on the learnings of the afternoon | |
| 17:40 | Soccer game North vs South of the World | |
| 19:30 | Alumni presentations | 3 alumni from diverse background: Sonali Kochhar , Global Healthcare Consulting; Kamel Senouci , Bill & Melinda Gates Foundation; Charles Wiysonge , South African Medical Research Centre |

| WEDNESDAY 18 MAY 2022 | | |
|---|--|--|
| SESSION 9 - SELECTING APPROPRIATE VACCINATION STRATEGIES | | Chairperson: Janet Englund, Children's Hospital and Regional Medical Center, Seattle, USA |
| 09:00-09:25 | Vaccination and pregnancy: Scientific basis, main issues and applications | Janet Englund, Children's Hospital and Regional Medical Center, Seattle, USA |
| 09:25-09:45 | Discussion | |
| 09:45-10:10 | Vaccination in early life | Christiane Eberhardt, University of Geneva |
| 10:10-10:30 | Discussion | |
| 10:30-11:00 | Break | |
| 11:00-11:25 | Vaccination schedules: Past, present and future - is there some rationale? | Edwin Asturias, Children's Hospital Colorado, USA |
| 11:25-11:45 | Discussion | |
| 11:45-12:10 | Influenza biology, new vaccines and vaccination strategies for different age groups | Kathy Neuzil, Center for Vaccine Development, University of Maryland, Baltimore, |
| 12:10-12:30 | Discussion | |
| 12:30-12:40 | Time for students to reflect personally on the learnings of the morning | |
| 12:40-13:10 | Buffet lunch | |
| 13:10-15:40 | Parallel working group sessions | |
| | 1. National decision-making for immunization programmes | Christoph Steffen, WHO and Philippe Duclos, ADVAC |
| | 2. Clinical vaccinology: patients' problem solving | Alessandro Diana, University of Geneva, and Christiane Eberhardt, University of Geneva |
| | 3. New approaches towards vaccination e-registries | Julia Stowe, Public Health England, UK, Carolina Danovaro, WHO Geneva, and Kari Johansen, Public Health Institute, Sweden |
| | 4. Cold Chain management | Souleymane Kone, WHO Geneva and Collins Tabu, Immunization Manager, Kenya |
| 15:40-16:00 | Break | |
| 16:00-16:25 | Vaccination in immuno-compromised individuals, including HIV positive patients | Janet Englund, Children's Hospital and Regional Medical Center, Seattle, USA |
| 16:25-16:45 | Discussion | |
| 16:45-17:10 | History of vaccines and vaccination | Stanley Plotkin, University of Pennsylvania, USA |
| 17:10-17:30 | Discussion | |
| 17:30-17:40 | Time for students to reflect personally on the learnings of the afternoon | |
| | Special lecture: THE 14TH PLOTKIN LECTURE | |
| 17:40-17:45 | Introduction and Chair | Edwin Asturias, Children's Hospital Colorado, USA |
| 17:45-18:25 | Vaccine vector platforms for COVID-19 | Dan Barouch, Harvard University, USA |
| 18:25-18:45 | Discussion | |

| THURSDAY 19 MAY 2022 | | |
|---|---|--|
| SESSION 10: VACCINES UNDER DEVELOPMENT | | Chairperson: Edwin Asturias , Children's Hospital Colorado, USA |
| 08:30-08:55 | Vaccines against epidemic and orphan diseases: How new technologies can change vaccine development | Barney Graham , formerly Vaccine Research Center, NIAID, NIH, Bethesda, USA |
| 08:55-09:15 | Discussion | |
| 09:15-09:40 | The challenge of malaria vaccines and of their potential introduction | Mary Hamel , WHO, Geneva |
| 09:40-10:00 | Discussion | |
| 10:00-10:30 | Break | |
| 10:30-10:55 | Global challenges for pertussis vaccines | Kathy Edwards , Vanderbilt Vaccine Research Program, USA |
| 10:55-11:15 | Discussion | |
| 11:15-11:40 | HIV vaccines | Roger Le Grand , Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases, France |
| 11:40-12:00 | Discussion | |
| 12:00-12:10 | Time for students to reflect personally on the learnings of the morning | |
| 12:10-13:10 | Buffet lunch | |
| 13:10-13:35 | Challenges and prospects for new tuberculosis vaccines | Helen McShane , University of Oxford, UK |
| 13:35-13:55 | Discussion | |
| SESSION 11: OUTBREAKS' CONTROL: ELIMINATION AND ERADICATION STRATEGIES | | Chairperson: Stanley Plotkin , University of Pennsylvania, USA |
| 13:55-14:20 | Immunization coverage gaps: overcoming the chronic challenges | Kate O'Brien , WHO, Geneva |
| 14:20-14:40 | Discussion | |
| 14:40-15:05 | Polio | Ananda Bandyopadhyay , Bill & Melinda Gates Foundation, USA |
| 15:05-15:25 | Discussion | |
| 15:25-15:55 | Break | |
| 15:55-16:20 | Diphtheria, measles and rubella | Ann Lindstrand , WHO, Geneva |
| 16:20-16:40 | Discussion | |
| SESSION 12: RECAP | | Chairperson: Philippe Duclos , University of Geneva |
| 16:40-18:30 | Panel: Answers to questions from participants | Pieter Neels , Vaccine-advice, Belgium; Alejandro Cravioto , Chair of SAGE; Arnaud Didierlaurent , University of Geneva; Ilesh Jani , National Institute of Health, Mozambique; Romina Libster , Fundación INFANT/ National Scientific and Technical Research Council/ Vanderbilt University; Ann Lindstrand , WHO Geneva; Robin Nandy , UNICEF; Stanley Plotkin , University of Pennsylvania, USA |
| 18:30-18:40 | Time for students to reflect personally on the learnings of the afternoon | |
| 19:00 | Departure to Château de Menthon Visit and special reception | |

| FRIDAY 20 MAY 2022 | | |
|---|---|---|
| SESSION 13: FACING THE MEDIA: WHAT THE VACCINOLOGIST SHOULD KNOW IN THE CONTEXT OF VACCINE HESITANCY AND ANTI-IMMUNIZATION LOBBY | | Chairperson: Philippe Duclos , University of Geneva |
| 08:30-10:30 | Interactive session: Introduction to media dynamics: How to best deliver vaccinology-related messages to different interest groups | Deborah Hall , Broadcaster and Media Affairs Consultant, London, UK |
| 10:30-10:50 | Break | |
| 10:50-13:00 | Introduction to media dynamics: How to best deliver vaccinology-related messages to different interest groups (continued) | |
| 13:00-14:00 | Lunch | |
| SESSION 12: RECAP (Ctd) | | |
| 14:00-14:40 | Highlights from ADVAC 2022 | Romina Libster , Fundación INFANT/ National Scientific and Technical Research Council/ Vanderbilt University |
| 14:40 | Diploma ceremony, awarding of CME credits and closure of the Course | Alain Mérieux , President, Fondation Mérieux and Philippe Duclos , University of Geneva |

| SESSION 1b - Special lectures from Industry | | |
|--|---|---|
| 15:20-15:45 | Role of LMIC vaccine industry for meeting global needs | Sunil Gairola , Executive Director, Serum Institute of India, Pune, India |
| 15:45-16:05 | Discussion | |
| 16:05-16:30 | Development and production of vaccines for global use: the role of vaccine industry | Luis Jodar , Senior Vice President and Chief Medical Officer, Vaccines, Pfizer Inc., USA |
| 16:30-16:50 | Discussion | |